Protection against Escherichia coli O157:H7 challenge by immunization of mice with purified Tir proteins
Protection against Escherichia coli O157:H7 challenge by immunization of mice with purified Tir proteins
复制标题
DOI：
10.1007/s11033-011-0824-0
复制
发表时间：
2012-02-01
影响因子：
2.8
通讯作者：
Long, Bei-guo
中科院分区：
文献类型：
--
作者：
Fan, Hong-ying;Wang, Ling;Long, Bei-guo
肠出血性大肠杆菌（EHEC）O157：H7感染在世界范围内引起严重的公共卫生问题。转位的内膜受体（Tir）负责粘附、附着和消退病变。在当前的研究中，我们使用丝裂霉素处理的小鼠模型来评估皮下与鼻内施用重组Tir作为疫苗的功效。免疫后，小鼠感染E. coli O157：H7，并监测面部的脱落。与皮下免疫或对照免疫相比，用纯化的Tir蛋白免疫的小鼠在血清和粪便中产生更高的IgG和伊加滴度，导致EHEC O157的粪便脱落显著减少，存活率更高（92.9%）。这些结果证明了在粘膜疫苗制剂中使用Tir蛋白以防止大肠杆菌定殖和脱落的潜力。coli O157：H7。因此，纯化的Tir鼻内免疫后保护小鼠免受EHEC攻击，值得进一步临床开发作为疫苗候选物。
Enterohemorrhagic Escherichia coli (EHEC) O157:H7 infections cause serious public health problems worldwide. The translocation intimin receptor (Tir) is responsible for adhesion and attaching and effacing lesions. In the current study, we used a mitomycin-treated mouse model to evaluate the efficacy of subcutaneous vs intranasal administration of the recombinant Tir as vaccine. Following immunization, mice were infected with E. coli O157:H7 and faces were monitored for shedding. Mice immunized intrasally with purified Tir proteins produced higher IgG and IgA titers in serum and feces, resulting in significant reductions in fecal shedding of EHEC O157 and higher a survival rate (92.9%), compared with subcutaneous or control immunizations. These results demonstrate the potential for the use of Tir proteins in mucosal vaccine formulations to prevent colonization and shedding of E. coli O157:H7. Therefore, purified Tir protects mice against EHEC challenge after intranasal immunization and is worth further clinical development as a vaccine candidate.